Myriad Genetics Inc reports results for the quarter ended in March - Earnings Summary

Myriad Genetics

08/05/2024 01:25

* Myriad Genetics Inc  MYGN.OQ  reported a quarterly
adjusted loss
of 1 cent​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -21 cents.  The mean expectation of twelve analysts for the
quarter was for a loss of 10 cents per share. Wall Street
expected results to range from -18 cents to -3 cents per share.
    * Revenue rose 11.6% to $202.20 million from a year ago;
analysts
expected $193.51 million. 
    * Myriad Genetics Inc's reported EPS for the quarter was a
loss
of 29 cents​.
    * The company reported a quarterly loss of $26 million.
    * Myriad Genetics Inc shares had fallen by 6.3% this
quarter and
gained 4.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 135.5% in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 5
"hold" and 3 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Myriad Genetics
Inc is $25.00 
This summary was machine generated from LSEG data May 8 at 12:25
a.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.10          -0.01          Beat
 Dec. 31 2023      0.01           0.04           Beat
 Sep. 30 2023      -0.08          -0.03          Beat
 Jun. 30 2023      -0.08          -0.08          Met